Member access

4-Traders Homepage  >  Shares  >  OTC Bulletin Board  >  Cannabis Science Inc       US1376481016

SummaryNewsCompany 

Cannabis Science, Inc. : Cannabis Science Reports Second Cancer Patient Receives Clean Biopsy Report Confirming the Biopsy is Free of Cancer Cells

04/04/2012 | 01:15pm US/Eastern
Recommend:
0

Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.

Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, "Squamous cell carcinomas have a much greater invasive potential than is typical of basal cell carcinomas. Photo-documentation of topical cannabis extract treatments of patient #2 and patient #3 dramatically demonstrate how the treatment appear to extrude the subcutaneous tumor to the surface as the killing and subsequent healing proceeds. Patient #3 reports continued progress as his tumors appear to shrink and the pain levels continue to improve. The patient's wife commented that about 75% of the large tumor mass is gone. We will continue with 'live updates' as new pictures and physician reports are made available to us."

You can view the patient's photographs during the treatment process, as well as the full biopsy report from the physician, on the Cannabis Science website www.cannabisscience.com. Click the button "View Images of 2nd Self-Medicated Patient & The Apparent Success" to view the full biopsy report, photos and additional information.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
VP Investor Relations
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com


© Business Wire 2012
Recommend :
0
React to this article
Latest news on CANNABIS SCIENCE INC
08/18 CANNABIS SCIENCE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
08/14 CANNABIS SCIENCE : Material Modification to Rights of Security Holders (form 8-K..
08/08 CANNABIS SCIENCE : Entry into a Material Definitive Agreement (form 8-K)
08/06 CANNABIS SCIENCE : Initiates Pre-Clinical Studies on Cannabinoid Formulations in..
08/04 CANNABIS SCIENCE : Initiates Scientific Cultivation Programs to Test Multiple St..
07/30 CANNABIS SCIENCE : Dr. Robert Melamede Joins Cannabis Professional University in..
07/25 CANNABIS SCIENCE : Appoints Dr. Roscoe M. Moore Jr., US Assistant Surgeon Genera..
07/23 CANNABIS CAPITAL : CBCA Changes Name to Crown Baus Capital Corp., Better Reflect..
07/21 CANNABIS SCIENCE : CFO Journal, addresses business challenges of cannabis indust..
06/12 CANNABIS SCIENCE : CBIS Reports on CBS News; Historic Marijuana Vote from United..
Advertisement
Dynamic quotes  
ON
| OFF